Deubiquitinase inhibitor PR‐619 potentiates colon cancer immunotherapy by inducing ferroptosis
Authors:
- 1 August 2023
- journal article
- research article
- Published by Wiley in Immunology
- Vol. 170 (3) , 439-451
Abstract
A substantial number of colon cancer patients do not benefit from immunotherapy using programmed cell death 1 (PD1) antibodies. Therefore, combination therapy drugs are required to improve the efficacy of colon cancer immunotherapy. Recent studies have shown that deubiquitinases are negative regulators of anti‐tumour immunity. In the present study, we investigated the effect of the deubiquitinase inhibitor PR‐619 in combination with anti‐PD1 for the treatment of colorectal cancer. The results revealed that co‐treatment with PR‐619 and anti‐PD1 significantly inhibited tumour growth in tumour‐bearing BALB/c mice compared to monotherapy with a single drug. In addition, PR‐619/anti‐PD1 combined therapy inhibited cell proliferation, promoted cell apoptosis, induced intratumor infiltration of CD8+ T cells, and enhanced the release of anti‐tumour cytokines. Moreover, PR‐619 induced ferroptosis in colon cancer cells, thereby inducing the release of damage‐associated molecular patterns that triggered anti‐tumour immunity. Finally, we discovered that PR‐619 could degrade the GPX4 protein, the high expression of which was associated with poor prognosis and blocked CD8+ T cells infiltration in colon cancer. In conclusion, PR‐619 may potentiate immunotherapy by inducing ferroptosis, and thereby promoting CD8+ T cells‐mediated anti‐tumour immunity, providing a potential strategy for colon cancer treatment.Keywords
Funding Information
- National Natural Science Foundation of China (82103318)
This publication has 38 references indexed in Scilit:
- Ubiquitin Signaling and Degradation of Aggregate-Prone ProteinsTrends in Biochemical Sciences, 2019
- The Tumor Microenvironment Innately Modulates Cancer ProgressionCancer Research, 2019
- Role of GPX4 in ferroptosis and its pharmacological implicationFree Radical Biology and Medicine, 2019
- Breaking the chains: deubiquitylating enzyme specificity begets functionNature Reviews Molecular Cell Biology, 2019
- CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A reviewJournal of Cellular Physiology, 2018
- Abstract 108: In vitro and in vivo characterization of novel scorpion venom-based peptides for the treatment of colon cancerCancer Research, 2017
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapyAnnals of Oncology, 2016
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating EnzymesChemistry & Biology, 2011
- Deubiquitinases in cancer: new functions and therapeutic optionsOncogene, 2011